Faculty profile

Robert Kridel

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Robert Kridel

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
48 publications in the last five years, latest in 2026.
Senior (last) author on 8 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2025.
Supervisor on 4 trainee awards (4 CIHR), most recently in 2026.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Histone Deacetylases Lymphoma Preclinical Efficacy Targeted Protein Degradation Targeted Therapy

Latest papers

CAR-T for Management of R/R PTLD Following Lung Transplant: A Multi-center Retrospective Study
Transplantation and Cellular Therapy · 2026
Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.
Blood · 2026
Detection and classification of lymphoma from cell-free methylome data.
NPJ precision oncology · 2026 · senior author

All 74 publications

Latest funding

Epigenetic Targeting to Enhance Immune Therapies in B-cell Lymphoma
CIHR · 2026 · Supervisor
$140,000
Therapeutic targeting of the tumour microenvironment in post-transplant lymphoproliferative disorder
CIHR · 2025 · Supervisor
$120,000
Establishing the Preclinical Efficacy of a Dual HDAC3/8 Degrader for the Treatment of Diffuse Large B-Cell Lymphoma
CIHR · 2025 · Nominated PI
$795,600

All 6 grants and awards

74 publications.

CAR-T for Management of R/R PTLD Following Lung Transplant: A Multi-center Retrospective Study

Salter B, Suleman A, Kridel R, Trottier AM, Li R, Binnie M, Balitsky AK, Davies GA

Transplantation and Cellular Therapy20263 citations

DOI: 10.1016/j.jtct.2025.10.006

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Vodička P, El-Galaly TC, Procházka V, Flowers CR, Villa D, Dietrich CE, Jakobsen LH, Ghesquières H, Clausen MR, Kridel R, Cheah CY, Hawkes EA, Wahlin B, Gandhi MK, Larson MC, Cahn EJ, Friedberg JW, Martin P, Chihara D, Cohen JB, Habermann TM, Casulo C, Wang Y, de Nully Brown P, Mou E, Belada D, Janíková A, Móciková H, Burack R, Lossos IS, Kahl BS, Smedby KE, Sehn LH, Trněný M, Cerhan JR, Maurer MJ

Blood2026

DOI: 10.1182/blood.2026033090 PMID: 41980013

Detection and classification of lymphoma from cell-free methylome data.

Shelton VB, Alias M, Liu T, Zhao D, Alamilla P, Singhawansa A, Hong M, Zeng Y, Murad V, Alrekhais I, Metser U, Hodgson D, Aoki T, Prica A, Kuruvilla J, Crump M, Lam B, Hoffman MM, Bratman SV, Kridel R

NPJ precision oncology2026Senior author

DOI: 10.1038/s41698-026-01533-8 PMID: 42236545

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Aoki T, Duns G, Rai S, Jiang A, Lytle A, Yin Y, Kishida M, Yu Li M, Lee C, Smorra D, Hilton LK, Healy S, Alig SK, Shahrokh Esfahani M, Sarkozy C, Hung SS, Milne K, Telenius A, O'Brien L, Wong JCH, Cassidy C, Fujisawa M, Strong C, Goodyear T, Di Vito C, Luksik C, Edin G, Gonzalez L, Rangel Patiño J, Hong M, Wu S, Lee E, Sakhdari A, Takata K, Miyata-Takata T, Boyle M, Ben-Neriah S, Weng AP, Xu A, Merchant A, Roth A, Crump M, Kuruvilla J, Prica A, Kridel R, Huntsman DG, Nelson BH, Farinha P, Morin RD, Alizadeh AA, Savage KJ, Scott DW, Steidl C

Cancer discovery2026

DOI: 10.1158/2159-8290.cd-25-0859 PMID: 41615883

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Kordbacheh T, Chan KKW, Crump M, Ante Z, Liu N, Aminilari M, Gong IY, Bhella S, Vijenthira A, Kuruvilla J, Kridel R, Chen C, Kukreti V, Yang C, Hodgson D, Prica A, Rodin D

Blood advances2026

DOI: 10.1182/bloodadvances.2025017401 PMID: 41544221

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Merryman R, Rutherford SC, Ansell S, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman J, Zelenetz AD, Gutierrez M, Béguelin W, Casulo C, Cerhan J, Green M, Kahl B, Kridel R, Link B, Maurer MJ, Nadel B, Radtke AJ, Luttwak E, Salles G, Sehn L, Pasqualucci L, LaCasce AS

Blood advances2026

DOI: 10.1182/bloodadvances.2025018079 PMID: 41337699

Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy.

Liao D, Aminilari M, Ye XY, Metser U, Singnurkar A, Bhella S, Crump M, Kridel R, Kukreti V, Kuruvilla J, Prica A, Vijenthira A, Cheung M, Rodin D, Tsao M, Hodgson D

Practical radiation oncology2026

DOI: 10.1016/j.prro.2026.01.017 PMID: 41765363

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Gong IY, Jeeva M, Hueniken K, Aminilari M, Marinoni M, Prica A, Rodin D, Bhella S, Aoki T, Azab M, Chen C, Kridel R, Kukreti V, Vijenthira A, Yang C, Malik N, Wells W, Metser U, Crump M, Hodgson D, Kuruvilla J

Hematological oncology2026

DOI: 10.1002/hon.70183 PMID: 41774783

Blood-based epigenetic instability linked to human aging and disease.

Basrai S, Nofech-Mozes I, Detroja R, Scolari FL, Bakhtiari M, Arruda A, Murphy T, Bratman SV, Chan SM, Minden MD, Sook Ahn J, Kim DDH, Kridel R, Billia F, Abelson S

Nature communications2026

DOI: 10.1038/s41467-026-69430-z PMID: 41690920

Correction: Added prognostic value of baseline pre-infusion 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy.

Mirshahvalad SA, Kohan A, Kulanthaivelu R, Ortega C, Metser U, Hodgson D, Kridel R, Chen C, Bhella S, Veit-Haibach P

Scientific reports2026

DOI: 10.1038/s41598-026-36849-9 PMID: 41606040

Something wrong or missing on this profile? Suggest a correction

Robert Kridel

Research

Latest papers

Latest funding

CAR-T for Management of R/R PTLD Following Lung Transplant: A Multi-center Retrospective Study

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Detection and classification of lymphoma from cell-free methylome data.

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy.

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Blood-based epigenetic instability linked to human aging and disease.

Correction: Added prognostic value of baseline pre-infusion 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy.

Epigenetic Targeting to Enhance Immune Therapies in B-cell Lymphoma

Therapeutic targeting of the tumour microenvironment in post-transplant lymphoproliferative disorder

Establishing the Preclinical Efficacy of a Dual HDAC3/8 Degrader for the Treatment of Diffuse Large B-Cell Lymphoma

Elucidation of the tumor microenvironment of Hodgkin lymphoma post immunotherapy

Building a platform for advancing Canadian science in lymphoma: A strategic planning workshop of the Canadian Lymphoma Consortium (CLyC)

Delineation of the molecular heterogeneity underlying patient outcomes in follicular lymphoma

Frequent collaborators

John Kuruvilla

Christian Steidl

David Hodgson

Danielle Rodin

Aly Karsan

Wei Xu

Patrick Veit-Haibach

Jan Delabie

David Lebrun

Nathalie Johnson

Tracy Stockley

Armand Keating

Emilia Lim

Osvaldo Espin Garcia

Ning Liu

Marco Marra

Razqallah Hakem

Amaris Karin Balitsky

Filio Billia

Trevor Pugh

Dean Regier

Michael Reedijk

Phedias Diamandis

Ali Bashashati

Mathieu Lupien

Regina Li